Slate Path Capital LP Arrowhead Pharmaceuticals, Inc. Transaction History
Slate Path Capital LP
- $5.36 Billion
- Q3 2025
A detailed history of Slate Path Capital LP transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Slate Path Capital LP holds 4,982,000 shares of ARWR stock, worth $206 Million. This represents 3.21% of its overall portfolio holdings.
Number of Shares
4,982,000
Previous 5,232,000
4.78%
Holding current value
$206 Million
Previous $82.7 Million
107.86%
% of portfolio
3.21%
Previous 1.65%
Shares
5 transactions
Others Institutions Holding ARWR
# of Institutions
339Shares Held
103MCall Options Held
953KPut Options Held
263K-
Vanguard Group Inc Valley Forge, PA16MShares$662 Million0.01% of portfolio
-
Black Rock Inc. New York, NY15.7MShares$647 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY10.9MShares$450 Million5.14% of portfolio
-
State Street Corp Boston, MA6.4MShares$264 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.13MShares$129 Million0.01% of portfolio
About ARROWHEAD PHARMACEUTICALS, INC.
- Ticker ARWR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 105,849,000
- Market Cap $4.37B
- Description
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...